Phaseline

Targets › AURKA

AURKA (Aurora kinase A): drug programs, companies and trials

2 programs from 2 companies in 6 trials: 4 Phase 2, 2 Phase 1; Oncology; next expected readout Aug 2027.

Mitotic serine/threonine kinase that contributes to the regulation of cell cycle progression. Associates with the centrosome and the spindle microtubules during mitosis and plays a critical role in various mitotic events including the establishment of mitotic spindle, centrosome duplication, centrosome separation as well as maturation, chromosomal alignment, spindle assembly checkpoint, and cytokinesis. (UniProt, O14965)

Open in Phaseline: the race on AURKA, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Puma BiotechnologyAlisertib
Serine/threonine-protein kinase Aurora-A inhibitor
AURKAPhase 2Small Cell Lung Cancer; Hormone Receptor Positive HER-2 Negative Breast Cancer; Small Cell Lung Cancer ( SCLC ); Malignant Rhabdoid Tumor …Oct 2027
Jacobio PharmaceuticalsJAB-2485
Aurora A inhibitor
AURKAPhase 1Solid TumorsAug 2027

Conditions

Small Cell Lung Cancer (1) Hormone Receptor Positive HER-2 Negative Breast Cancer (1) Small Cell Lung Cancer ( SCLC ) (1) Malignant Rhabdoid Tumor (1) Recurrent B-Cell Non-Hodgkin Lymphoma (1) Solid Tumors (1)

Modalities

small molecule (2)

Companies

Puma Biotechnology (1) Jacobio Pharmaceuticals (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.